BETRF:OTC-BetterLife Pharma Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.0825

Change

-0.01 (-6.14)%

Market Cap

USD 0.01B

Volume

0.01M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-29 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
ARGNF argenx SE

N/A

USD 34.32B
UCBJY UCB SA ADR

+2.52 (+2.85%)

USD 33.77B
UCBJF UCB SA

+3.64 (+2.07%)

USD 33.01B
WXIBF WuXi Biologics

N/A

USD 12.07B
WXXWY WuXi Biologics (Cayman) Inc

-0.14 (-2.10%)

USD 12.07B
GNMSF Genmab A/S

-2.00 (-0.95%)

USD 12.01B
IVBIY IVBIY

N/A

USD 11.04B
AKESF Akeso, Inc.

-0.45 (-4.14%)

USD 9.60B
SBHMY Sino Biopharmaceutical Ltd ADR

N/A

USD 9.28B
SBMFF Sino Biopharmaceutical Limited

N/A

USD 8.94B

ETFs Containing BETRF

CRAK VanEck Oil Refiners ETF 9.06 % 0.60 %

+0.03 (+-1.26%)

USD 0.02B
GNR SPDR® S&P Global Natural.. 2.84 % 0.40 %

-0.16 (-1.26%)

USD 2.74B
XSOE WisdomTree Emerging Marke.. 1.78 % 0.32 %

-0.38 (-1.26%)

N/A
GMF SPDR® S&P Emerging Asia .. 1.49 % 0.49 %

-1.26 (-1.26%)

USD 0.36B
SPEM SPDR® Portfolio Emerging.. 1.27 % 0.12 %

-0.50 (-1.26%)

USD 11.42B
AVEM Avantis® Emerging Market.. 0.79 % 0.00 %

-0.82 (-1.26%)

USD 8.32B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 14.58% 71% C- 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 14.58% 71% C- 64% D
Trailing 12 Months  
Capital Gain -6.25% 64% D 49% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -6.25% 64% D 47% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -21.84% 29% F 14% F
Dividend Return -21.84% 29% F 14% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 56.16% 56% F 45% F
Risk Adjusted Return -38.89% 33% F 20% F
Market Capitalization 0.01B 54% F 39% F

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.